PT832094E - Compostos de aminoesterol uteis como inibidores do permutador sodio/protao )nhe) metodos e composicoes farmaceuticas empregando estes inibidores e processos para avaliacao da eficacia inibidora de nhe dos compostos - Google Patents
Compostos de aminoesterol uteis como inibidores do permutador sodio/protao )nhe) metodos e composicoes farmaceuticas empregando estes inibidores e processos para avaliacao da eficacia inibidora de nhe dos compostosInfo
- Publication number
- PT832094E PT832094E PT96922490T PT96922490T PT832094E PT 832094 E PT832094 E PT 832094E PT 96922490 T PT96922490 T PT 96922490T PT 96922490 T PT96922490 T PT 96922490T PT 832094 E PT832094 E PT 832094E
- Authority
- PT
- Portugal
- Prior art keywords
- compounds
- inhibitors
- evaluating
- methods
- processes
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5061—Muscle cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Virology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/483,059 US5840740A (en) | 1995-06-07 | 1995-06-07 | Aminosterol compounds and a method of treating infection using the aminosterol compounds |
US08/475,572 US5840936A (en) | 1995-06-07 | 1995-06-07 | Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE) |
US08/476,855 US5874597A (en) | 1995-06-07 | 1995-06-07 | Certain aminosterol compounds and pharmaceutical compositions including these compounds |
US08/487,443 US5847172A (en) | 1995-06-07 | 1995-06-07 | Certain aminosterol compounds and pharmaceutical compositions including these compounds |
US08/479,457 US5763430A (en) | 1995-06-07 | 1995-06-07 | Method of treating a viral infection by administering a steroid compound |
US08/479,455 US5994336A (en) | 1995-06-07 | 1995-06-07 | Method of inhibiting proliferation of cells by administering an aminosterol compound |
US08/483,057 US5795885A (en) | 1995-06-07 | 1995-06-07 | Method of inhibiting profileration of cells by administering an aminosterol compound |
Publications (1)
Publication Number | Publication Date |
---|---|
PT832094E true PT832094E (pt) | 2004-06-30 |
Family
ID=27569803
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT96922490T PT832094E (pt) | 1995-06-07 | 1996-06-07 | Compostos de aminoesterol uteis como inibidores do permutador sodio/protao )nhe) metodos e composicoes farmaceuticas empregando estes inibidores e processos para avaliacao da eficacia inibidora de nhe dos compostos |
Country Status (10)
Country | Link |
---|---|
EP (2) | EP1420027A3 (pt) |
JP (2) | JP4104164B2 (pt) |
AT (1) | ATE259375T1 (pt) |
AU (1) | AU723663C (pt) |
CA (1) | CA2223910C (pt) |
DE (1) | DE69631527T2 (pt) |
DK (1) | DK0832094T3 (pt) |
ES (1) | ES2216049T3 (pt) |
PT (1) | PT832094E (pt) |
WO (1) | WO1996040728A2 (pt) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5856535A (en) * | 1994-08-18 | 1999-01-05 | Magainin Pharmaceuticals, Inc. | Aminosterol ester compounds |
US5792635A (en) * | 1995-06-07 | 1998-08-11 | Magainin Pharmaceuticals, Inc. | Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine |
US6143738A (en) * | 1995-06-07 | 2000-11-07 | Magainin Pharmaceuticals, Inc. | Therapeutic uses for an aminosterol compound |
CA2252584C (en) * | 1996-04-26 | 2008-06-10 | Magainin Pharmaceuticals Inc. | Treatment of carcinomas using squalamine in combination with other anti-cancer agents |
US6596712B2 (en) | 1996-04-26 | 2003-07-22 | Genaera Corporation | Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities |
US7410959B1 (en) | 2000-07-13 | 2008-08-12 | Genaera Corporation | Therapeutic uses for aminosterol compounds |
EP0923377A1 (en) * | 1996-05-17 | 1999-06-23 | Magainin Pharmaceuticals Inc. | Therapeutic uses for an aminosterol compound |
WO1998019682A1 (en) * | 1996-11-01 | 1998-05-14 | Magainin Pharmaceuticals Inc. | Certain aminosterol compounds and uses therefor |
US6262283B1 (en) * | 1996-12-06 | 2001-07-17 | Magainin Pharmaceuticals Inc. | Stereoselective synthesis of 24-hydroxylated compounds useful for the preparation of aminosterols, vitamin D analogs, and other compounds |
DE19737463A1 (de) * | 1997-08-28 | 1999-03-04 | Hoechst Marion Roussel De Gmbh | Verwendung von Inhibitoren des Natrium-Wasserstoff-Austauschers zur Herstellung eines Arzneimittels zur Behandlung von Erkrankungen, die durch Protozoen verursacht werden |
EP1274718B1 (en) | 2000-04-12 | 2006-10-18 | Genaera Corporation | A process for the preparation of 7.alpha.-hydroxy 3-aminosubstituted sterols using intermediates with an unprotected 7.alpha.-hydroxy group |
WO2006119211A2 (en) * | 2005-05-02 | 2006-11-09 | Genaera Corporation | Methods and compositions for treating ocular disorders |
US20080058300A1 (en) * | 2006-04-21 | 2008-03-06 | Mclane Michael | Induction of weight loss and the selective inhibition of PTP1B |
CA2985271A1 (en) * | 2007-09-06 | 2009-03-12 | Ohr Pharmaceutical, Inc. | A method for treating diabetes |
WO2009135583A1 (en) * | 2008-05-09 | 2009-11-12 | Merck Patent Gmbh | Pharmaceutical composition comprising rimeporide for treating diseases associated with insulin resistance and beta-cell dysfunction |
PL2758060T3 (pl) | 2011-09-19 | 2018-04-30 | ETH Zürich | Modulatory ROR-gamma do leczenia powikłań cukrzycy typu II |
TR201911039T4 (tr) | 2012-04-20 | 2019-08-21 | Ohr Pharmaceutical Inc | Ptp1b ile ilişkili bir hastalığın tedavisine yönelik aminosteroidler. |
US11524015B2 (en) | 2013-03-15 | 2022-12-13 | Brigham Young University | Methods for treating inflammation, autoimmune disorders and pain |
JP6518230B2 (ja) | 2013-03-15 | 2019-05-22 | ブリガム・ヤング・ユニバーシティBrigham Young University | 炎症、自己免疫疾患、および疼痛を治療する方法 |
EP2781217A1 (en) * | 2013-03-18 | 2014-09-24 | ETH Zurich | ROR gamma modulators |
US10040817B2 (en) | 2013-10-03 | 2018-08-07 | Enterin Laboratories, Inc. | Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same |
US11690855B2 (en) | 2013-10-17 | 2023-07-04 | Brigham Young University | Methods for treating lung infections and inflammation |
US20150203527A1 (en) | 2014-01-23 | 2015-07-23 | Brigham Young University | Cationic steroidal antimicrobials |
US10441595B2 (en) * | 2014-06-26 | 2019-10-15 | Brigham Young University | Methods for treating fungal infections |
FR3033563B1 (fr) * | 2015-03-12 | 2018-04-13 | Virbac | Composes analogues de la squalamine utiles comme agents antibacteriens |
FR3055801B1 (fr) * | 2016-09-15 | 2020-10-30 | Virbac | Derives esters de squalamine pour le traitement des infections |
WO2019050903A1 (en) * | 2017-09-08 | 2019-03-14 | Enterin Laboratories, Inc. | METHODS OF TREATING SLEEP DISORDERS, SLEEP DISTURBANCES AND ASSOCIATED SYMPTOMS USING AMINOSTEROL COMPOSITIONS |
EP3829587A4 (en) * | 2018-08-03 | 2022-07-20 | Enterin, Inc. | COMPOSITIONS AND METHODS FOR TREATING GUT-BRAIN AXIS DISORDERS |
US11464789B2 (en) | 2018-08-03 | 2022-10-11 | Enterin, Inc. | Aminosterol compositions and methods of using the same for treating schizophrenia |
CN112782300B (zh) * | 2020-12-25 | 2022-04-12 | 山东省食品药品检验研究院 | 一种胆烷酸的同分异构体及其检测方法和应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5192756A (en) * | 1992-03-18 | 1993-03-09 | The Children's Hospital Of Pennsylvania | Aminosterol antibiotic |
AU6392894A (en) * | 1993-02-26 | 1994-09-14 | Magainin Pharmaceuticals, Inc. | Chemical synthesis of squalamine |
CA2157594A1 (en) * | 1993-03-10 | 1994-09-15 | Leah L. Frye | Steroid derivatives, pharmaceutical compositions containing them, and their use as antibiotics or disinfectants |
-
1996
- 1996-06-07 CA CA002223910A patent/CA2223910C/en not_active Expired - Lifetime
- 1996-06-07 DE DE69631527T patent/DE69631527T2/de not_active Expired - Lifetime
- 1996-06-07 EP EP04002943A patent/EP1420027A3/en not_active Withdrawn
- 1996-06-07 DK DK96922490T patent/DK0832094T3/da active
- 1996-06-07 EP EP96922490A patent/EP0832094B1/en not_active Expired - Lifetime
- 1996-06-07 AT AT96922490T patent/ATE259375T1/de not_active IP Right Cessation
- 1996-06-07 PT PT96922490T patent/PT832094E/pt unknown
- 1996-06-07 JP JP50230797A patent/JP4104164B2/ja not_active Expired - Lifetime
- 1996-06-07 AU AU63349/96A patent/AU723663C/en not_active Ceased
- 1996-06-07 ES ES96922490T patent/ES2216049T3/es not_active Expired - Lifetime
- 1996-06-07 WO PCT/US1996/010508 patent/WO1996040728A2/en active IP Right Grant
-
2007
- 2007-08-29 JP JP2007223309A patent/JP2007314577A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP0832094A2 (en) | 1998-04-01 |
WO1996040728A3 (en) | 1997-03-27 |
WO1996040728A2 (en) | 1996-12-19 |
EP1420027A2 (en) | 2004-05-19 |
CA2223910C (en) | 2008-09-16 |
CA2223910A1 (en) | 1996-12-19 |
DE69631527T2 (de) | 2004-09-23 |
ES2216049T3 (es) | 2004-10-16 |
JP2007314577A (ja) | 2007-12-06 |
JP4104164B2 (ja) | 2008-06-18 |
ATE259375T1 (de) | 2004-02-15 |
AU723663C (en) | 2001-11-01 |
AU723663B2 (en) | 2000-08-31 |
DK0832094T3 (da) | 2004-05-17 |
AU6334996A (en) | 1996-12-30 |
JP2002515019A (ja) | 2002-05-21 |
DE69631527D1 (de) | 2004-03-18 |
EP1420027A3 (en) | 2012-01-04 |
EP0832094B1 (en) | 2004-02-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT832094E (pt) | Compostos de aminoesterol uteis como inibidores do permutador sodio/protao )nhe) metodos e composicoes farmaceuticas empregando estes inibidores e processos para avaliacao da eficacia inibidora de nhe dos compostos | |
ZA964819B (en) | Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE), pharmaceutical methods and compositions employing such inhibitors, and processes for evaluating the NHE-inhibitory efficacy of compounds. | |
IL115597A (en) | Dihalopropene compounds and insecticidal/acaricidal compositions containing same | |
DK0943328T3 (da) | Kombinationsterapi til profylakse og/eller behandling af godartet prostatahyperplasi | |
DE69505490D1 (de) | Dihalopropenverbindungen, sie enthaltende insektizide/akarizide mittel, und zwischenprodukte | |
DE69628019D1 (de) | Chinolone und deren therapeutische verwendung | |
ES2137628T3 (es) | Derivados de estilbeno y composiciones farmaceuticas que los contienen. | |
ATE225351T1 (de) | Thienopyridin und thienopyrimidinderivate und ihre verwendung als entzündungshemmende mittel | |
PT750618E (pt) | Derivados de oxazolidinona e composicoes farmaceuticas que os contem | |
ES2179071T3 (es) | Agentes vasodilatadores perifericos que comprenden como principio activo derivados de la piperidina 4-amino n-acilada. | |
DE69534564D1 (de) | Verwendung von 2-hydroxy-5-phenylazobenzoesäure-derivaten als wirkstoffe zur chemoprävention und chemotherapie von kolonkrebs | |
ES2169127T3 (es) | Nuevos carbamatos y ureas como modificadores de la resistencia multi-farmaco. | |
AR001592A1 (es) | Composicion herbicida y metodo de control de malezas | |
PT896533E (pt) | Pentafluorobenzenosulfonamidas e analogos | |
ZA964818B (en) | Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE), pharmaceutical methods and compositions employing such inhibitors, and processes for evaluating the NHE-inhibitory efficacy of compounds. | |
DK0679393T3 (da) | Pharmaceutisk præparat til behandling af osteoporose indeholdende xanthohumol | |
DK0888323T3 (da) | Dihydrobenzofuran og beslægtede forbindelser, der er nyttige som antiinflammatoriske midler | |
RU94031161A (ru) | Фармацевтическая композиция и способ ее получения, способ лечения нарушений, развивающихся вследствие нейродегенеративных процессов | |
DE69613395D1 (de) | Schwefelenthaltende di-ter-butylphenol-verbindungen brauchbar als entzündungshemmende mittel | |
TR199700452A2 (xx) | B�cek ve zararl� kenelerin imhas�na mahsus maddeler. | |
ES2101373T3 (es) | Tetrahidrociclopent(b)indol-metaminas y compuestos relacionados, un procedimiento para su preparacion y su uso como medicamentos. | |
ATE248830T1 (de) | Substituierte 2,3-aryl-benzothiophene und ihre östrogene aktivität | |
DE19780042D2 (de) | Therapeutische Mittel, enthaltend organische Selenverbindungen gegen Asthma | |
ATE141259T1 (de) | N-substituierte carbonyloxyalkylpyrrol enthaltende insekticide, acarizide und molluskizide mittel | |
DE69834243D1 (de) | Fotoempfindliche zusammensetzungen und flexodruckplatte |